The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating on dentsply sirona despite first quarter challenges
DENTSPLY SIRONA shares fell 8.8% following disappointing first-quarter guidance, prompting UBS to maintain a Buy rating with a $27 price target. The company anticipates a high-single-digit organic revenue decline and flat earnings, attributed to challenges in the Clear Aligner Therapy Systems market. Despite recent struggles, analysts expect profitability in FY2025, with EPS forecasted at $1.88, while management remains optimistic about future growth through strategic initiatives and product launches.
ubs lowers cvs health price target amid mixed analyst outlook
UBS analyst Kevin Caliendo has lowered the price target for CVS Health from $62 to $59 while maintaining a Neutral rating, citing concerns over fourth-quarter earnings and the 2025 outlook. Despite a 21.85% year-to-date return, he notes a slightly positive near-term risk/reward balance and emphasizes the need for new management to rebuild investor trust. Other firms have varied in their assessments, with some raising price targets and maintaining optimistic ratings, reflecting the potential for a turnaround driven by strategic initiatives.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.